We are updating the design of this site. Learn more.
Show more
ClinicalTrials.gov
ClinicalTrials.gov Menu

Observational Study to Evaluate the Safety and Efficacy of NovoMix® 70 in Type 2 Diabetes (INTENSIV)

This study has been completed.
Sponsor:
ClinicalTrials.gov Identifier:
NCT00704223
First Posted: June 24, 2008
Last Update Posted: June 24, 2014
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
Information provided by (Responsible Party):
Novo Nordisk A/S
June 20, 2008
June 24, 2008
June 24, 2014
May 2008
November 2008   (Final data collection date for primary outcome measure)
number of major and minor hypoglycaemic events and adverse events [ Time Frame: 3 months ]
Same as current
Complete list of historical versions of study NCT00704223 on ClinicalTrials.gov Archive Site
  • HbA1c [ Time Frame: 3 months ]
  • PPBG [ Time Frame: 3 months ]
  • FBG [ Time Frame: 3 months ]
Same as current
Not Provided
Not Provided
 
Observational Study to Evaluate the Safety and Efficacy of NovoMix® 70 in Type 2 Diabetes
Observational Study on Safety and Efficacy in Subjects Using NovoMix® 70 (Biphasic Insulin Aspart) for Treatment of Type 2 Diabetes Mellitus
This study is conducted in Europe. The aim of this observational study is to evaluate the incidence of adverse events while using NovoMix® 70 under normal clinical practice conditions in Austria.
Not Provided
Observational
Observational Model: Cohort
Time Perspective: Prospective
Not Provided
Retention:   Samples With DNA
Description:
Blood sample
Probability Sample
Male and female above 18 years with type 2 diabetes
  • Diabetes
  • Diabetes Mellitus, Type 2
Drug: biphasic insulin aspart
Start dose and frequency to prescribed by the physician as a result of a normal clinical evaluation
Other Name: NovoMix® 70
A
Intervention: Drug: biphasic insulin aspart
Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Completed
619
November 2008
November 2008   (Final data collection date for primary outcome measure)

Inclusion Criteria:

  • Type 2 diabetes
  • HbA1c over 7%
  • No contraindication with NovoMix® 70

Exclusion Criteria:

  • Type 1 diabetes
  • Subjects participating in a clinical trial or another observational study
  • Subjects under previous basis-bolus insulin therapy
  • Women who are pregnant, breast feeding and women of child bearing capacity who are not using any reliable contraceptive method
Sexes Eligible for Study: All
18 Years and older   (Adult, Senior)
No
Contact information is only displayed when the study is recruiting subjects
Austria
 
 
NCT00704223
BIASP-3576
No
Not Provided
Not Provided
Novo Nordisk A/S
Novo Nordisk A/S
Not Provided
Study Director: Global Clinical Registry (GCR, 1452) Novo Nordisk A/S
Novo Nordisk A/S
June 2014